Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer

Journal of Nuclear Medicine

Volumn 56, Issue 4, 2015, Pages 523-529

  Kaneko, Yui ^a   Murray, William K ^a   Link, Emma ^a   Hicks, Rodney J ^a   Duong, Cuong ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

FDG PET; Gastric cancer; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; SLC2A1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; STOMACH CANCER; SYSTEMATIC REVIEW; TUMOR VOLUME; VERY ELDERLY; ADENOCARCINOMA; CARCINOMA; CARCINOMA, SIGNET RING CELL; DIAGNOSTIC USE; METABOLISM; MIDDLE AGED; OBSERVER VARIATION; PROCEDURES; PROSPECTIVE STUDY; SCINTISCANNING; STOMACH NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CARCINOMA, SIGNET RING CELL; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; OBSERVER VARIATION; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS;

EID: 84928239656     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.150946     Document Type: Article

References (32)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-2150.
2. Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer. 1998;78:521-527.
3. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg. 1995;60:1573-1581.
4. 18F-FDG: a comparative analysis. J Nucl Med. 2007;48:1945-1950.
5. Chen J, Cheong JH, Yun MJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer. 2005;103:2383-2390.
6. 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg. 2004;28:247-253.
7. 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging. 2006;33:148-155.
8. 18F-FDG PET: a comparison study with CT. J Nucl Med. 2005;46:1582-1588.
9. Ha TK, Choi YY, Song SY, Kwon SJ. F18-fluorodeoxyglucose-positron emission tomography and computed tomography is not accurate in preoperative staging of gastric cancer. J Korean Surg Soc. 2011;81:104-110.
10. Oh HH, Lee SE, Choi IS, et al. The peak-standardized uptake value (P-SUV) by preoperative positron emission tomography-computed tomography (PET-CT) is a useful indicator of lymph node metastasis in gastric cancer. J Surg Oncol. 2011;104:530-533.
11. 18F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer. 2012;118:5481-5488.
12. Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003;30:288-295.
13. Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer. 2006;9:192-196.
14. Karp JS, Muehllehner G. Standards for performance measurements of PET scanners: evaluation with the UGM PENN-PET 240H scanner. Med Prog Technol. 1991;17:173-187.
15. 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun. 2010;31:532-538.
16. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92:634-641.
17. 18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med. 2006;20:597-604.
18. Kaemmerer D, Peter L, Lupp A, et al. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012;5:187-194.
19. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318.
20. Ott K, Herrmann K, Lordick F, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14:2012-2018.
21. 18F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making? Eur J Nucl Med Mol Imaging. 2011;38:64-73.
22. Hallinan JT, Venkatesh SK. Gastric carcinoma: imaging diagnosis, staging and assessment of treatment response. Cancer Imaging. 2013;13:212-227.
23. 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: computed tomography for preoperative staging in gastric cancer patients. J Gastric Cancer. 2012;12:179-186.
24. Chung HW, Lee SY, Han HS, et al. Gastric cancers with microsatellite instability exhibit high fluorodeoxyglucose uptake on positron emission tomography. Gastric Cancer. 2013;16:185-192.
25. Kim J, Sun CL, Mailey B, et al. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol. 2010;21:152-160.
26. Kim EY, Lee WJ, Choi D, et al. The value of PET/CT for preoperative staging of advanced gastric cancer: comparison with contrast-enhanced CT. Eur J Radiol. 2011;79:183-188.
27. Li B, Zheng P, Zhu Q, Lin J. Accurate preoperative staging of gastric cancer with combined endoscopic ultrasonography and PET-CT. Tohoku J Exp Med. 2012;228:9-16.
28. Hur H, Kim SH, Kim W, Song KY, Park CH, Jeon HM. The efficacy of preoperative PET/CT for prediction of curability in surgery for locally advanced gastric carcinoma. World J Surg Oncol. 2010;8:86-92.
29. 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2009;36:382-388.
30. Namikawa T, Okabayshi T, Nogami M, Ogawa Y, Kobayashi M, Hanazaki K. Assessment of F-fluorodeoxyglucose positron emission tomography combined with computed tomography in the preoperative management of patients with gastric cancer. Int J Clin Oncol. 2014;19:649-655.
31. Hur H, Xuan Y, Kim YB, et al. Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int J Oncol. 2013;42:44-54.
32. 18F]fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer. J Exp Clin Cancer Res. 2013;32:34-41.